Skip to main content

Share story

Infrastructure

Porting Zephyr RTOS to Synaptics SR100 AI MCUs

Porting Zephyr RTOS to Synaptics SR100 AI MCUs Image: Primary
Antmicro announced support for the Synaptics Astra SR100 MCU series in the Zephyr RTOS. The company is a longtime contributor to the Zephyr Project and provides software services for porting the operating system to new platforms. This marks the first Synaptics platform supported in Zephyr. The SR100 series includes single core SR102 and SR105 variants as well as the dual core SR110. The SR110 combines an Arm Cortex M55 CPU with an Arm Ethos U55 NPU and a low power Cortex M4 coprocessor. These components enable vision and audio processing on battery powered devices for uses including robotics and security sensors. The implementation is now available on GitHub. It includes support for Synaptics SR100 SoCs, the SR100 Astra Machina Micro RDK Board, and specific drivers. The drivers added are for clock control, pinctrl, reset, and AON GPO functions.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Antmicro and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.